Other names: MIR26A, MIRN26A1 HGNC (Hugo): MIR26A1 Location: 3p22.2 Local order: Within one intron of CTDSPL (CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like, CTDSPL).
DNA/RNA

Note
The 22-bp precursor microRNA 26a-1 holds complete conservation among Human, Rhesus, Mouse and Dog. MIR26A1 functions as tumor suppressor gene in hepatocellular carcinoma (Ji et al., 2009; Kota et al., 2009) , breast cancer , rhabdomyosarcoma (Ciarapica et al., 2009 ) and MYCinduced lymphoma (Sander et al., 2008) . Additionally, MIR26A1 potentially plays an important role in regulating IFN-β anti-inflammatory signaling (Witwer et al., 2010) .
The precursor MIR26A1 is composed of 77 nucleotides and its stem-loop structure is shown here. The sequence of mature MIR26A1 is marked in red.
Description
The precursor MIR26A1 maps on chromosome 3p22.2 spanning 77 bp and is located within one intron of CTDSPL (CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like, CTDSPL).
Transcription
The MIR26A1 gene is initially transcribed as a primary transcript in the nucleus and then further processed by the Drosha-Pasha/DGCR8 complex as an intermediate named the precursor microRNA 26a-1. After exported into cytoplasm by Exportin-5, the precursor microRNA 26a-1 was cleaved by Dicer as a duplex and in turn forms the mature 22-bp MIR26A1.
Mutations
Note None.
Implicated in
Hepatocellular carcinoma (HCC)
Note MIR26A is reduced in hepatocellular carcinoma and directly suppresses the expression of ERα (estrogen receptor alpha, ERα) , cyclin D2 and cyclin E2 (Kota et al., 2009 ). The overexpression of MIR26A negatively regulates cell proliferation and cell cycle (Kota et al., 2009) . Systemic administration of MIR26A in a mouse model of HCC using adeno-associated virus (AAV) results in inhibition of cancer cell proliferation, induction of tumor-specific apoptosis, and dramatic protection from disease progression without toxicity (Kota et al., 2009) . 
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Nasopharyngeal carcinoma (NPC)
Note MIR26A is commonly downregulated in NPC specimens and NPC cell lines and directly suppresses the expression of EZH2 (enhancer of zeste homolog 2, EZH2) (Lu et al., 2011) . Ectopic expression of MIR26A inhibits growth and colony formation of NPC cells by inducing G1-phase cell-cycle arrest. MIR26A also suppresses tumorigenesis of NPC cells in vivo. MIR26A suppressed the expression of c-myc, cyclins D3 and E2, and cyclin-dependent kinases CDK4 and CDK6 while enhancing the expression of CDK inhibitors p14 ARF and p21 CIP1 in an EZH2-dependent manner.
Breast cancer
Note MIR26A is downregulated in breast cancer specimens and cell lines and directly regulates the expression of MTDH (metadherin, MTDH) and EZH2 . MIR26A leads to apoptosis, inhibition of colony forming and in vivo tumorigenesis of breast cancer cells.
Rhabdomyosarcoma
Note
In rhabdomyosarcoma, MIR26A is underexpressed while the mRNA of EZH2 is increased. EZH2 is one of direct targets of MIR26A in several different cell lines (Ciarapica et al., 2009; Lu et al., 2011; Zhang et al., 2011) .
Airway smooth muscle hypertrophy
Note Stretch selectively induces the transcription of MIR26A in human airway smooth muscle cells (HASMCs). The transcription factor CCAAT enhancer-binding protein α (C/EBPα) directly activates miR-26a expression through the transcriptional machinery upon stretch. Glycogen synthase kinase-3β (GSK-3β) is a direct target of MIR26A (Mohamed et al., 2010) . The enforced expression of MIR26A induces HASMC hypertrophy.
Myogenesis
Note MIR26A is up-regulated during myogenesis and directly targets EZH2. Overexpression of MIR26A in murine myogenic C2C12 cells induced creatine kinase activity. Moreover, myoD and myogenin mRNA expression levels were also up-regulated. Therefore, increased expression of miR-26a promotes myogenesis (Wong and Tellam, 2008) .
Osteogenic differentiation
Note
During hADSC (human adipose tissue-derived stem cells, hADSCs) differentiation, MIR26A shows increased expression. The inhibition of miR-26a increases protein levels of its predicted target, SMAD1 transcription factor (Luzi et al., 2008) .
